News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
734,103 Results
Type
Article (41827)
Company Profile (266)
Press Release (691996)
Multimedia
Podcasts (105)
Webinars (20)
Section
Business (205100)
Career Advice (2037)
Deals (35654)
Drug Delivery (134)
Drug Development (81731)
Employer Resources (174)
FDA (16555)
Job Trends (15007)
News (347319)
Policy (32815)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2606)
Accelerated approval (56)
ADA (44)
Adcomms (28)
Allergies (190)
Alliances (49637)
ALS (222)
Alzheimer's disease (1878)
Antibody-drug conjugate (ADC) (500)
Approvals (16990)
Artificial intelligence (703)
ASCO (327)
Autoimmune disease (332)
Automation (58)
Bankruptcy (362)
Best Places to Work (11641)
BIOSECURE Act (20)
Biosimilars (231)
Biotechnology (172)
Bladder cancer (200)
Brain cancer (74)
Breast cancer (788)
Cancer (6190)
Cardiovascular disease (498)
Career advice (1733)
Career pathing (44)
CAR-T (351)
CDC (57)
Celiac Disease (3)
Cell therapy (945)
Cervical cancer (53)
Clinical research (71439)
Collaboration (2160)
Commercialization (1)
Company closure (5)
Compensation (1469)
Complete response letters (86)
COVID-19 (2756)
CRISPR (113)
C-suite (1201)
Cystic fibrosis (155)
Data (8509)
Decentralized trials (3)
Denatured (28)
Depression (175)
Dermatology (94)
Diabetes (655)
Diagnostics (7007)
Digital health (63)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (343)
Drug pricing (203)
Drug shortages (32)
Duchenne muscular dystrophy (297)
Earnings (92221)
Editorial (66)
Employer branding (22)
Employer resources (153)
Events (120496)
Executive appointments (1111)
FDA (20462)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (20)
Frontotemporal dementia (35)
Funding (1806)
Gene editing (241)
Generative AI (60)
Gene therapy (739)
GLP-1 (1089)
Government (4759)
Grass and pollen (6)
Guidances (415)
Healthcare (19153)
Hematology (192)
HIV (87)
Huntington's disease (59)
IgA nephropathy (110)
Immunology and inflammation (299)
Immuno-oncology (101)
Indications (207)
Infectious disease (3117)
Inflammatory bowel disease (218)
Inflation Reduction Act (15)
Influenza (139)
Intellectual property (312)
Interviews (320)
IPO (16683)
IRA (50)
Job creations (3658)
Job search strategy (1434)
JPM (60)
Kidney cancer (20)
Labor market (109)
Layoffs (573)
Leadership (42)
Legal (7973)
Liver cancer (103)
Longevity (34)
Lung cancer (823)
Lymphoma (467)
Machine learning (62)
Management (59)
Manufacturing (1117)
Marketing (1)
MASH (205)
Medical affairs (1)
Medical device (13978)
Medtech (14133)
Mergers & acquisitions (20263)
Metabolic disorders (1627)
mRNA (224)
Multiple sclerosis (195)
NASH (17)
Neurodegenerative disease (462)
Neuropsychiatric disorders (112)
Neuroscience (3491)
Neurotech (1)
NextGen: Class of 2026 (6537)
Non-profit (4543)
Now hiring (79)
Obesity (752)
Opinion (299)
Ovarian cancer (235)
Pain (264)
Pancreatic cancer (336)
Parkinson's disease (383)
Partnered (34)
Patents (625)
Patient recruitment (731)
Peanut (66)
People (59866)
Pharmaceutical (59)
Pharmacy benefit managers (33)
Phase 1 (22272)
Phase 2 (31475)
Phase 3 (23432)
Pipeline (9553)
Policy (330)
Postmarket research (2575)
Preclinical (9468)
Press Release (64)
Prostate cancer (332)
Psychedelics (56)
Radiopharmaceuticals (340)
Rare diseases (1146)
Real estate (5980)
Recruiting (71)
Regulatory (25715)
Reports (56)
Research institute (2422)
Resumes & cover letters (354)
Rett syndrome (42)
RNA editing (24)
RSV (89)
Schizophrenia (183)
Series A (303)
Series B (224)
Service/supplier (11)
Sickle cell disease (118)
Special edition (28)
Spinal muscular atrophy (175)
Sponsored (48)
Startups (3660)
State (2)
Stomach cancer (18)
Supply chain (133)
Tariffs (87)
The Weekly (75)
Vaccines (1134)
Venture capital (116)
Weight loss (480)
Women's health (134)
Worklife (20)
Date
Today (110)
Last 7 days (553)
Last 30 days (2853)
Last 365 days (30451)
2026 (15260)
2025 (30204)
2024 (35239)
2023 (40095)
2022 (51219)
2021 (55748)
2020 (54109)
2019 (46573)
2018 (35049)
2017 (32165)
2016 (31549)
2015 (37587)
2014 (31338)
2013 (26356)
2012 (28583)
2011 (29273)
2010 (27334)
Location
Africa (752)
Alabama (93)
Alaska (7)
Arizona (362)
Arkansas (14)
Asia (39925)
Australia (6545)
California (13834)
Canada (3895)
China (1455)
Colorado (591)
Connecticut (605)
Delaware (430)
Europe (86419)
Florida (2074)
Georgia (441)
Hawaii (3)
Idaho (63)
Illinois (1126)
India (95)
Indiana (625)
Iowa (24)
Japan (579)
Kansas (133)
Kentucky (51)
Louisiana (58)
Maine (76)
Maryland (1650)
Massachusetts (9900)
Michigan (373)
Minnesota (748)
Mississippi (6)
Missouri (147)
Montana (33)
Nebraska (29)
Nevada (147)
New Hampshire (84)
New Jersey (3623)
New Mexico (30)
New York (3622)
North Carolina (1745)
North Dakota (9)
Northern California (6976)
Ohio (414)
Oklahoma (23)
Oregon (41)
Pennsylvania (2756)
Puerto Rico (30)
Rhode Island (52)
South America (1120)
South Carolina (86)
South Dakota (2)
Southern California (5476)
Tennessee (221)
Texas (2213)
United States (48774)
Utah (410)
Vermont (1)
Virginia (337)
Washington D.C. (81)
Washington State (1104)
West Virginia (4)
Wisconsin (132)
Wyoming (2)
734,103 Results for "biogen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
If Biogen has shown that tau can impact cognition, Denali’s technology—validated with an FDA approval in Hunter syndrome—could ensure the medicine gets where it needs to be for the greatest therapeutic impact, analysts said.
May 15, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
June 8, 2026
·
5 min read
Alzheimer’s disease
Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer’s market as patients end their 18-month course of Lilly’s product.
April 29, 2026
·
3 min read
·
Annalee Armstrong
Parkinson’s disease
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop
Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints.
May 22, 2026
·
2 min read
·
Tristan Manalac
Earnings
With growth curve trending up, Biogen looks to early-stage assets for ‘next generation’
Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the pressure and cleared the way for some early-stage bets, CEO Chris Viehbacher said Wednesday.
April 29, 2026
·
3 min read
·
Annalee Armstrong
Alzheimer’s disease
Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism
While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted biomarker and cognitive improvements from the Phase 2 study, leaving analysts eager for more data.
May 14, 2026
·
3 min read
·
Tristan Manalac
Alzheimer’s disease
Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy
The FDA’s extension will give reviewers more time to review a major amendment to Biogen and Eisai’s application for a subcutaneous induction formulation of Alzheimer’s therapy Leqembi. The new target action date is on Aug. 24.
May 8, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials.
March 31, 2026
·
4 min read
·
Annalee Armstrong
Earnings
Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline
With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth.
February 6, 2026
·
2 min read
·
Annalee Armstrong
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
1 of 73,411
Next
